S. aureus secretes other toxins that are also able to target phagocytes, lymphocytes and erythro cytes, including α-toxin, β-toxin and small cytotoxic peptides known as phenol-soluble modulins (PSMs) 8, 13 . Bi-component leukocidins are a collection of PFTs produced by many staphylococci. PFTs are generally secreted as inactive monomeric subunits that multimerize on binding to the membrane of a target host cell, which results in the formation of a pore that spans the phospholipid bilayer and induces cell death (FIG. 1) . On the basis of the secondary structure of the membrane-spanning domains, PFTs are classified into α-helical PFTs or β-barrel PFTs 14 . β-Barrel PFTs are further classified into cholesterol-dependent cyto lysins or haemolysins; the staphylococcal bi-component leukocidins belong to the haemolysin class of toxins. S. aureus isolates that are associated with human infections can produce up to five different leukocidins: Panton-Valentine leukocidin (PVL or LukSF-PV), γ-haemolysin AB and γ-haemolysin CB (HlgAB and HlgCB), leukocidin ED (LukED) and leukocidin AB (LukAB; also known as LukGH) 7 (TABLE 1).
The other leukocidins that are known to be produced by S. aureus are leukocidin MFʹ (LukMFʹ) 15 and leukocidin PQ (LukPQ) 16 ; however, these toxins are associated with zoonotic infections and are rarely found in human isolates of S. aureus (BOX 1) . Although the first description of leukocidin activity in S. aureus culture supernatants was published around 1895, (the discoveries that lead to the identification
Bi-component leukocidins
Toxins that consist of two protein subunits that hetero-oligomerize to form multimeric pores. The pores penetrate the lipid bilayer of the target cell.
Leukocytes
A generic term used to describe immune cells that are of haematopoietic origin.
Phagocytes
Immune cells that specifically engulf and degrade bacteria, fungi, parasites, dead host cells, and cellular and foreign debris by a process termed phagocytosis.
Phenol-soluble modulins (PSMs) . Small amphipathic peptides produced by staphylococci that exhibit cytotoxic activity against host cells.
of the leukocidins were recently reviewed elsewhere; see REF. 7 ), the molecular mechanisms that cause pore formation have remained incompletely understood.
Bi-component leukocidins are thought to protect S. aureus from being killed by host phagocytes; however, the necessity of the apparently redundant range of phagocyte-targeting toxins is incompletely understood. The ability of the bi-component leukocidins to target and kill human leukocytes in vitro has been established and supported by more 100 years of research 12 ; however, whether they target and kill human leukocytes in vivo to promote S. aureus infection remains controversial 3 . This controversy is a result of the poor understanding of the molecular mechanisms that underlie the differential cellular tropism and species specificity exhibited by these toxins (TABLE 1) . Moreover, an incomplete awareness that animal leukocytes are not as susceptible to leukocidins as human leukocytes has hindered progress in understanding the contribution of the bi-component leukocidins to staphylococcal pathophysiology 12, 17 . During the past five years, the receptors that are targeted by staphylococcal leukocidins have been identified, which has helped to explain the cellular tropism and species specificity of these toxins. The identification of these receptors has also enabled the role of each individual leukocidin to be assessed and has improved our understanding of the complex interplay between different leukocidins during infection. In addition to their cytotoxic potential, the discovery of the leukocidin receptors has revealed new insights into how leukocidins modulate immune cell functions. Similarly, the identification of an erythroid receptor for leukocidins has also provided new insights into the link between virulence and nutritional immunity. This Review provides an overview of the similarities and differences in the interactions between leukocidins and their respective receptors, and discusses the implications of receptor identification for the mechanisms of action of leukocidins, their diverse roles during pathogenesis in vivo and their potential as targets for therapeutic interventions.
Leukocidins and receptors
Leukocidin structures. The bi-component leukocidins are PFTs that share a highly conserved structure 18 ( FIG. 1a) . All of the subunits of the different leukocidins have an approximate molecular weight of 33 kDa. Leukocidins have two subunits that are classified as the host cell targeting S component (for slow migration in chromatography columns: LukS-PV, LukE, HlgA, HlgC and LukA), and the polymerization F component (for fast migration: LukF-PV, LukD, HlgB and LukB) 7 (TABLE 1). In contrast to the S components and F components of other leukocidins, which are secreted as two soluble and independent monomers, LukAB is pre-assembled as a soluble heterodimer 19 . Both the S component and the F component have three important domains -a cap, a rim and a stem (FIG. 1a) . In the soluble form, the hydrophobic stem region is packed within the cap domain. The oligomerization of leukocidins is thought to induce a conformational change in each component that causes the extension and unfolding of the stem domain, 
HlgAB ¶ HlgA (S type) and HlgB (F type)
HlgCB HlgC (S type) and HlgB (F type) 18 . During oligomerization, a ring-shaped pre-pore is formed that enables the multimeric β-strand domains of the stem regions to be inserted into the cell membrane, which results in the formation of a pore that is 1-2 nm in diameter 18, 20 (FIG. 1a) . Structural studies of HlgAB and HlgCB have revealed that these leukocidins form an octameric pore that has alternating HlgA or HlgC and HlgB subunits 18, 20 (FIG. 1a) . Similarly, LukAB was recently found to form a hetero-octameric pore 21 . On the basis of the crystal structure of the LukAB heterodimer, the sites of interaction between LukA and LukB help to explain why this toxin is pre-assembled in solution 21, 22 . Three salt bridges between the interfaces For all of the bi-component leukocidins except LukAB, which binds to its target as a pre-assembled dimer, the initial binding of the S component to the host cell is followed by the recruitment of the F component [25] [26] [27] (FIG. 1b) . During the multimerization of the S component and the F component, a pre-pore is formed that eventually spans the entire membrane. F components have also been shown to interact with the surface of neutrophils independently of the S component [28] [29] [30] ; nevertheless, the cellular target, or targets, and the importance of this binding to pore formation by the bi-component leukocidins remain to be fully elucidated. Most leukocidins can form functional pores using both cognate (for example, LukED and HlgAB) and non-cognate combinations of subunits (for example, LukE-HlgB and HlgA-LukD) [31] [32] [33] (TABLE 1) . This is true for PVL, LukED, HlgAB and HlgCB, but not for the pre-assembled LukAB dimer, which does not interact with any of the other leukocidin subunits owing to its structural divergence 21 (TABLE 1) . The functional consequences of cognate and non-cognate interactions between the bi-component leukocidins are discussed below.
Leukocidin receptors. The distinct cellular and species specificities of the bi-component leukocidins (TABLE 1) have provided historical clues for the involvement of specific proteinaceous host receptors. In 2011, three receptors were described for LukED and PVL in different laboratories. For LukED, CC-chemokine receptor 5 (CCR5) was identified as a receptor 10 . Concurrently, C5a anaphylatoxin chemotactic receptor 1 (C5aR1) and C5aR2 were identified as the receptors for PVL 34 ( (TABLE 1) . The presence of the cognate leukocidin receptors on the surface of host target cells is required for leukocidin toxicity 10, [34] [35] [36] [37] [38] . Moreover, the interspecies variations in the sequence and structure of leukocidin receptors are responsible for the divergent susceptibility of immune cells from different mammalian species to leukocidins 34,36,37,39 (BOX 2; TABLE 1).
The majority of the receptors that are targeted by bi-component leukocidins belong to the families of complement and chemokine receptors (BOX 1), of which most are class A rhodopsin-like G protein-coupled receptors (GPCRs) -C5aR1, C5aR2, CXCR1, CXCR2, CCR2, CCR5 and DARC 40 . These structurally and functionally related seven-transmembrane-spanning receptors are involved in transducing extracellular signals to the interior of the cell through cytosolic G proteins. By contrast, DARC is an atypical chemokine receptor that is not coupled to a G protein 41, 42 . With the exception of DARC, these receptors are expressed in specific leukocytes at very high levels. Key cellular functions that are regulated by G proteins include cellular activation and migration 40 . CD11b is more distantly related to the family of GPCRs and a component of the Mac-1 integrin. The Mac-1 integrin is highly expressed on phagocytes and is involved in many crucial cellular functions, such as phagocytosis, cell-mediated killing and chemotaxis 43 .
Leukocidins and receptor interactions. The identification of the leukocidin receptors has led to detailed molecular studies of leukocidin-receptor interactions. Targeting of the receptors by leukocidins is mediated by S components, which bind to their receptors with high affinity (all within a nanomolar range) 10, [34] [35] [36] [37] [38] . The S components share 70-90% amino acid sequence identity 44
, and the alignment of leukocidin amino acid sequences has revealed divergent regions (DRs) in the rim of the S components 35 (FIG. 1a) . For LukED, DR1 is involved in the targeting of CCR5 by LukE 45 (FIG. 1b) , whereas DR4 determines the targeting of CXCR1 and CXCR2, but not of CCR5, by LukE 35 (FIG. 1b) . The identification of different regions in one leukocidin that are involved in the recognition of different receptors enabled the generation of mutant LukED toxins that
Box 1 | Leukocidins and non-human staphylococci
Recent studies on bi-component leukocidins have focused on those produced by human isolates of Staphylococcus aureus. However, S. aureus can also infect different animals, including pigs, rabbits, cattle, horses and dogs 118 . These zoonotic strains are likely to encode bi-component leukocidins in their genomes that enable them to target and kill neutrophils from different species. For example, leukocidin MFʹ (LukMFʹ) is a toxin that was found in S. aureus isolates from bovine infections 39, 119 . LukMFʹ has a remarkable cellular tropism for bovine phagocytes, a property that is mediated by the targeting of CC-chemokine receptor 1 (CCR1) 39 , which is a chemokine receptor that is expressed in bovine neutrophils but not in human neutrophils. More recently, a novel bi-component leukocidin, LukPQ, was identified in S. aureus isolates from horses 16 and is highly cytotoxic in equine neutrophils. LukPQ is similar to LukED (91% amino acid identity between LukE and LukP) 16 , and targets the equine CXC chemokine receptor A (CXCRA) and CXCR2 receptors on neutrophils.
The role of leukocidins in the pathogenesis of other staphylococcal species is exemplified by the leukocidin LukSF-I 15 , which is encoded by Staphylococcus pseudintermedius, a pathogen that is primarily associated with infections in canines. LukSF-I has substantial amino acid sequence similarity with LukED and can target canine and human phagocytes 15 . However, in contrast to LukED, LukSF-I has low haemolytic activity.
Bi-component leukocidin-like toxins have also been found in Staphylococcus argenteus, Staphylococcus schweitzeri and Staphylococcus delphini. S. argenteus and S. schweitzeri encode a toxin that is similar to the human LukAB leukocidin, whereas S. delphini (a zoonotic pathogen that infects dolphins) encodes a toxin that is similar to LukSF-I from S. pseudintermedius. Species diversification in leukocidins provides strong support for the notion that the targeting of phagocytes by staphylococci is crucial for host adaptation. only target CCR5 or CXCR1 and CXCR2, which subsequently enabled the relative importance of the different leukocidin-receptor interactions to be assessed in vivo 35 . For PVL, a cluster of amino acids in the bottom loops of the rim domain is essential for the recognition of C5aR1 by LukS-PV 46 (FIG. 1b) . It is likely that the amino acids that are conserved in LukS-PV and HlgC determine the specificity of these toxins for C5aR1 and C5aR2, which are their shared receptors. The molecular mechanism by which HlgAB targets different receptors is not understood. For LukAB, the LukA subunit has unique amino-terminal and carboxy-terminal extensions. Remarkably, one conserved amino acid within the C-terminal extension, a glutamic acid at position 323 in LukA, was found to be involved in the interaction between LukAB and CD11b 19 (FIG. 1b) . The salt bridge that mediates the dimerization of LukA-LukB in solution also seems to be essential for this leukocidin to efficiently bind to its receptor 21 . The molecular determinants in the receptor for the leukocidin-receptor interaction have also been investigated. For PVL and its receptor C5aR1, and for HlgAB and LukED and their shared erythroid receptor DARC, the sulfation of tyrosine residues in the N-terminal region of the receptor seems to be essential for leukocidinreceptor interactions 34, 38 (FIG. 1b) . Sulfated N-terminal tyrosine residues possibly define a conserved interaction site for leukocidins. By taking advantage of the differential species-specific engagement of PVL and HlgCB with their shared receptors C5aR1 and C5aR2, it was shown that different regions of the receptors are involved in binding and pore formation by these leukocidins 47 . The human specificity that is exhibited by PVL is determined by the second extracellular loop of C5aR1. In contrast to PVL, the specificity of HlgCB for C5aR1 is determined by the first and third extracellular loops of the receptor 47 . Differences in the interaction between PVL and HlgCB with C5aR1 have also been hypothesized, based on the use of specific C5aR1 antagonists in vitro. Although the toxicity of PVL can be inhibited by C5aR inhibitors, many of the inhibitors cannot neutralize the toxicity of HlgCB 47 . The specificity of LukAB for human CD11b is determined through its interaction with the receptor I-domain 37 , which is the binding site for many
Box 2 | Leukocidin and receptor co-evolution
The amino acid sequence identity between the leukocidin S components and F components is ~30% 110 . In their respective groups, the S components and F components share ~70% amino acid sequence identity 44 . Interestingly, leukocidin AB (LukAB) is more divergent from the other leukocidins, with an amino acid sequence identity of approximately 30% compared with other leukocidins 44 . The phylogenetic association between the different leukocidin S components from human isolates of Staphylococcus aureus is depicted below (see the figure). It is likely that the leukocidins have evolved from a common ancestor and by gene duplication 7 .
Host-pathogen co-evolution is thought to be a powerful determinant in the biology of infections 120 . Genes that are involved in immune evasion have a major role in host adaptation of S. aureus 48 . Comparing the phylogenetic associations of the leukocidins and their cognate receptors results in an evolutionary 'mirror', as the divergence of the leukocidin S components is reflected in the relatedness of the receptors that are targeted by the leukocidins. The phylogenetic associations of the human receptors that are targeted by leukocidins from human S. aureus isolates and phylogenetic associations of the leukocidin S components from a human S. aureus isolate (USA300-FPR3575) are presented below (see the figure; arrows indicate specific interactions between leukocidin S components and human receptors). Amino acid sequence comparisons were generated by ClustalW alignment using Lasergene MegAlign software (DNASTAR).
During evolution, protein structures are more conserved than the amino acid sequences. The sequence variation that evolved within the stable structure of the β-barrel leukocidins resulted in high-affinity protein-protein interactions with diverse receptor targets and may have also enabled the emergence of species-specific mutations that enabled S. aureus to adapt to humans, who are their major mammalian hosts 48 .
C5aR1, C5a anaphylatoxin chemotactic receptor 1; CCR2, CC-chemokine receptor 2; CXCR1, CXC chemokine receptor 1; DARC, Duffy antigen receptor for chemokines; HlgA, γ-haemolysin A; PV, Panton-Valentine.
Outgrowth
The multiplication of bacteria during an infection.
Peritonitis
Inflammation of the peritoneum (the lining of the inner abdominal wall) that is most often of infectious origin.
Core genome
Genes that are present in all Staphylococcus aureus strains.
Accessory genome
Genes that are present in subsets of Staphylococcus aureus strains only.
of the CD11b ligands (FIG. 1b) . With the exception of the conserved interaction of HlgAB and LukED with the sulfated N-terminal tyrosine residues of DARC, both toxins differentially interact with this receptor 38 . An N-terminal receptor residue that is involved in LukED-mediated, but not HlgAB-mediated, toxicity is also involved in the binding of the natural ligand interleukin-8 (IL-8; also known as CXCL8), which supports the notion that IL 10, [34] [35] [36] 38 . Although the interactions between leukocidin subunits and their respective receptors have been investigated, the number of receptors that contribute to the formation of the leukocidin pore is unknown. Similarly, how the leukocidins transition from a receptor-bound state to form octameric pores remains to be elucidated. Nevertheless, recent studies have revealed similarities and differences in the interactions between bi-component leukocidins and their respective receptors. These differences challenge the presumed functional redundancy of this family of toxins and provide an explanation for their cellular tropism and species specificity
.
Leukocidin genomic organization, regulation and expression. S. aureus has considerable variation in its gene content between strains, both in the core genome and the accessory genome 48 . The hlgACB and lukAB loci are located in the core genome and are present in more than 99.5% of human isolates of S. aureus. By contrast, genes that encode other leukocidins, such as PVL and LukED, are not as widely distributed 49, 50 . PVL is located in the temperate phage ΦSa2 (in the accessory genome) 51 and is found in less than 2% of all clinical isolates; however, the majority of community-acquired methicillin-resistant S. aureus (CA-MRSA) isolates in the United States contain the genes that encode PVL 52 . LukED is encoded in the stable S. aureus pathogenicity island vSaβ 53 , which is present in about 70% of all clinical isolates. For PVL, HlgCB, LukED and LukAB, the S component and the F component are found in an operon and are co-transcribed from a single promoter. By contrast, hlgA is transcribed as a single gene that is adjacent to the hlgCB locus 54 . The expression of bi-component leukocidins is complex and only partially understood. However, it is clear that S. aureus combines 'self-sensing' and 'host sensing' to regulate the expression of these toxins. Globally, the quorum sensing accessory gene regulator (Agr) system 55 , which is a self-sensing system, regulates the expression of leukocidin genes by controlling the production of the repressor of toxins (Rot), which is a helix-turn-helix (HTH)-type transcriptional regulator 56, 57 . In addition, several transcriptional regulators that control the Agr-Rot system, such as SarA, have been found to indirectly regulate the expression of certain leukocidins 56 . Interestingly, when S. aureus comes into contact with neutrophils or with human blood the expression of leukocidins is induced [58] [59] [60] [61] [62] . In this context, the host-sensing SaeRS two-component regulatory system, which consists of a histidine protein kinase (SaeS) and a response regulator (SaeR), is responsible for the observed enhanced expression of leukocidins [58] [59] [60] [61] [62] . Interestingly, the upregulation of lukAB expression following contact with neutrophils (a response that is mediated by the SaeRS system) 58, 60, 61 contributes to the ability of S. aureus to target and kill neutrophils 63 . Recent studies also suggest that S. aureus differentially regulates the expression of leukocidins by sensing metabolic shifts through a metabolite-sensing HTH-type transcriptional regulator known as RpiRc, which provides a link between metabolism and virulence 64 . Although our current understanding of leukocidin gene expression is incomplete, it is clear that the expression of leukocidins is regulated in response to environmental and metabolic cues.
Box 3 | Animal models and leukocidin research
The low cytotoxic activity of Panton-Valentine leukocidin (PVL), leukocidin AB (LukAB), γ-haemolysin CB (HlgCB) and HlgAB in murine polymorphonuclear neutrophils (PMNs) compared with human PMNs suggests that the reported activities of these toxins in murine models are underestimated, as murine phagocytes remain largely unaffected by these leukocidins. Currently, one of the best animal models to study the function of PVL is the rabbit 99, [121] [122] [123] [124] [125] . PVL has been shown to enhance the early stages of bacteraemic spread to the kidneys in a bloodstream infection model 125 and to contribute to osteomyelitis 123 . In a model of necrotizing pneumonia 124 , PVL has also been shown to be crucial for Staphylococcus aureus-mediated lung injury, pulmonary oedema, inflammation, increased levels of inflammatory cytokines and death. The increased lethality and pathologies observed with the PVL-producing strain in rabbits were associated with bacterial outgrowth, suggesting that this toxin also contributes to the growth of S. aureus in vivo. Importantly, purified PVL that was administered into the lungs recapitulated many of the observations with live S. aureus, which demonstrates that PVL alone can cause lung injury. PVL has been epidemiologically linked to skin and soft tissue infections (SSTI); however, the contribution of PVL to SSTI is controversial 98, 121 . Nevertheless, it is known that administering purified PVL into the skin of rabbits results in inflammation 99 and necrosis 122 . Notably, data that are generated using rabbit models should be interpreted with caution, as many rabbits have been previously exposed to S. aureus, resulting in the presence of antibodies 126 that could mask the contribution of virulence factors to infection and pathogenesis.
More recently, the contribution of PVL to the pathogenesis of S. aureus has also been evaluated in humanized mice 113, 114 . In these models, non-obese diabetic (NOD)/severe combined immune deficiency (SCID)/IL2Rγnull (NSG) mice were engrafted with primary human haematopoietic cells. Humanized mice were found to be more susceptible to S. aureus-mediated skin lesions 113 and pneumonia 114 than control mice, in a PVL-dependent manner. Together with the rabbit studies, these humanized mouse models reinforce the notion that PVL targets phagocytes during infection.
HlgAB and HlgCB have also been shown to contribute to infection. Initial studies that used an endophthalmitis rabbit model revealed that the HlgAB and HlgCB toxins are involved in inflammation of the eyelid and bacterial outgrowth 93 . Subsequent studies revealed that the presence of HlgAB and HlgCB mildly affected weight 92 and the survival of mice during bloodstream infections with S. aureus 62 . These data corroborate the observation that the receptor orthologues for HlgAB and HlgCB in murine neutrophils do not bind to these leukocidins 36 . By contrast, HlgAB is able to target both human and murine CC-chemokine receptor 2 (CCR2) in monocytes 36 . In a murine peritonitis model, HlgAB promoted bacteraemia in vivo in a CCR2-dependent manner 36 . Initially, bi-component leukocidins were only thought to target neutrophils, it is now clear that these toxins can also target natural killer cells, macrophages, dendritic cells and T lymphocytes. The innate and adaptive immunomodulatory activities of S. aureus could prevent the development of a functional and protective immune response. However, data to support this notion are limited, as a robust model to support the study of all of these toxins in vivo is currently lacking.
Self-sensing
Regulatory mechanisms by which bacteria coordinate information using stimuli provided by the bacterial population; for example, through the accessory gene regulator (Agr) quorum sensing system.
Host sensing
Regulatory mechanisms by which bacterial pathogens respond to stimuli provided by the host; for example, through the SaeRS system in Staphylococcus aureus.
Two-component regulatory system
Signal transduction modules that consist of a membrane receptor (sensor histidine kinase) and a transcription factor (response regulator) that enable bacteria to sense cues and coordinate a transcriptional response.
Pus
Exudate formed at the site of infection that mainly consists of debris from dead leukocytes.
Inflammasome
A multi-protein complex composed of inflammatory caspases, intracellular sensors (for example, nucleotidebinding domain, leucine-rich repeat containing protein or NLR), and the adaptor protein apoptosis-associated specklike protein containing a CARD (ASC) that is involved in pyroptosis and the processing of inflammatory cytokines.
Pyroptosis
A type of regulated necrosis that requires pore formation in the plasma membrane and results in cell swelling, ultimately causing massive leakage of cytosolic contents, which results in inflammation.
Necrosis
A non-apoptotic form of cell death that results in cell lysis and inflammation.
Cytokines
Small proteins that are involved in cell signalling that have immunomodulatory properties and act through receptors.
Gasdermin D
A host pore-forming protein that is responsible for cell lysis during pyroptosis.
A question that has concerned toxin researchers is whether the concentrations of toxin that are used in in vitro studies are biologically relevant during infections in vivo. In mammals, S. aureus is exposed to a range of environments and stresses that can influence gene expression in ways that are challenging to replicate in vitro. It is also unknown whether all leukocidins are expressed at the same time in vivo. Studies that have investigated the response of S. aureus following exposure to human blood or blood components have revealed the selective expression of leukocidin genes, in which the expression of HlgAB, HlgCB and LukAB is induced 62 . Another study found that LukAB seems to be the most upregulated leukocidin when S. aureus is exposed to human neutrophils 63 . These observations correlate with the contribution of these leukocidins to the survival of S. aureus (HlgAB and HlgCB) 62 or growth (LukAB) 63, 65, 66 in ex vivo models. Most studies that have tried to quantify leukocidin levels in vivo have focused on PVL. Pus samples from human infections contain up to 399 μg ml -1 PVL, a concentration that is about 1,000 fold higher than is required for PVL to kill a human neutrophil 67 , which supports the notion that S. aureus produces sufficient amounts of these toxins to target immune cells. Recent studies that used in vivo imaging systems 65 , mass spectometry 68 and RNA sequencing (RNA-seq) 69 have confirmed that leukocidins are produced during infection. These data are consistent with the observation that humans that are infected with S. aureus develop leukocidin-specific antibodies 70, 71 . Thus, these toxins are likely to contribute to pathogenesis in a leukocytetargeting-dependent manner. The various effects of leukocidins on cells at different concentrations are discussed in more detail in the following section.
Molecular mechanisms of action
Host cell death. Leukocidins can kill target cells at low concentrations (~1 nM) in vitro, and cell susceptibility is associated with receptor levels 10, 34, 35, 37, 38, 47, 72 . The formation of pores ultimately leads to the death of target cells through cell lysis, as it results in the leakage of divalent cations that are crucial for cell homeostasis (FIG. 2a) . During the past decade it has become clear that numerous PFTs use cellular pathways to enhance their ability to lyse cells. One such pathway is the inflammasome pathway 73 . Leukocidins, such as HlgAB, HlgCB, PVL and LukAB, are able to activate the NOD-, LRR-and pyrin domain-containing 3 (NLRP3) inflammasome in macrophages and monocytes [74] [75] [76] [77] , which promotes their lytic and pro-inflammatory activities. Leukocidin-mediated inflammasome activation seems to be dependent on the presence of cognate cellular receptors, which are required for leukocidins to form pores, as was recently shown for LukAB in human monocytes 76 . The mechanism by which each leukocidin activates NLRP3 is not fully understood, but it is thought that toxin pores in the plasma membrane result in the leakage of potassium ions from the cytoplasm of target cells, resulting in the activation of NLRP3 (REF. 78) (FIG. 2a) . The ability of leukocidins to form pores in the plasma membrane 33 provides an explanation as to how these toxins that target different receptors can all activate NLRP3. It is also possible that differences in leukocidin potency can be explained by differences in the signalling pathways that are used by the different cellular receptors (for example, GPCR versus integrin). Following activation, NLRP3 forms a cytoplasmic protein complex with apoptosis-associated speck-like protein containing a CARD (ASC) and caspase 1 that is known as the NLRP3 inflammasome, which can trigger pyroptosis (a necrosis-like cell death pathway) and the increased production of pro-inflammatory cytokines by macrophages [74] [75] [76] 79 . How leukocidin-mediated pores and the NLRP3 inflammasome work together to promote cell lysis is not fully understood. Recently, it has been shown that intracellular lipopolysaccharide (LPS)-induced pyroptotic cell death through caspase 4 (in mice) and caspase 4 and caspase 5 (in humans) mediates the cleavage of gasdermin D 80, 81 . The cleavage of gas dermin D results in the release of the N-terminal membrane-targeting domain, which promotes the assembly of the protein into pores that disrupt the membranes of mammalian cells 82, 83 . Moreover, the observation that caspase 1 can also cleave gasdermin D 80, 84 suggests that gas dermin D-mediated pore formation could also be involved in leukocidin-mediated pyroptotic cell death. If proven correct, this would suggest that host cells respond to damage from PFTs by producing their own intracellular pore-forming protein to cause cell death (FIG. 2a) . Detailed mechanistic studies of the pathways that are involved in the cell death of neutrophils -traditionally considered to be the major target of the leukocidins -are lacking and will be required to fully understand the role of leukocidins in promoting cell death.
Modulation of host cell signalling. In addition to killing cells, leukocidins can alter cell signalling pathways at sublytic concentrations (below 1 nM) in neutrophils and macrophages 75, 76, 79 , alter the activation status of neutrophils by priming the cells 34, 85 , and trigger the formation of neutrophil extracellular traps 86 (FIG. 2b) . Among the toxins, PVL and LukAB have been studied the most in the context of host cell signalling. Interestingly, PVL and LukAB can alter the cell in different ways. For example, PVL primes human neutrophils, which results in an enhanced production of superoxide in response to a secondary stimulus and enhanced phagocytic capacities 85 , whereas LukAB does not prime human neutrophils 86 . As single subunits, LukE, LukS-PV, HlgC and HlgA functionally antagonize their respective receptors in vitro 10, 34, 36 (FIG. 2b) . Owing to the clustering of S component and F component genes in a single operon, the significance of functional antagonism by a single S component during infection has not been studied. Nevertheless, studies on the non-lytic roles of leukocidins have highlighted the complexity of how each leukocidin can alter the function of their target cell. These effects are probably due to differential signalling of the targeted receptors. Future studies are required to further understand the effects that leukocidins have on leukocytes, and the contribution of these non-lytic effects to the pathophysiology of S. aureus. 
Neutrophil extracellular traps
Networks of extracellular fibres, primarily composed of DNA and antimicrobial peptides, that are released from neutrophils and bind to pathogens.
More than just leukocytes. In addition to inducing cell death in phagocytes, HlgAB and LukED can lyse erthyrocytes 32,38,87 (TABLE 1) . HlgAB and LukED promote the growth of S. aureus following erythrocyte lysis 38,87 (FIG. 2c) , which suggests that these toxins are involved in nutrient acquisition. Indeed, the lysis of erythrocytes results in the release of haemoglobin, which is the preferred iron source for the growth of S. aureus 6 . Iron is an essential metal for metabolism in many bacteria and is required for the pathogenesis of S. aureus. The ferric-uptake regulator (Fur), a major regulator of iron acquisition, regulates the expression of LukED, HlgAB and HlgCB 88 , which further indicates that leukocidins may have a role in nutrient acquisition during infection with S. aureus 38, 87 . DARC is the erythroid receptor for leukocidins 38 , and the S. aureus-mediated lysis of human erythrocytes is DARC-dependent (FIG. 2c; TABLE 1 ). The effect of the haemolytic activity of LukED and HlgAB in vivo has been challenging to study, as mutants that diminish the haemolytic activity of leukocidins without altering the leukocidal activity of the toxins remain to be 
Endophthalmitis
Inflammation of the internal eye that is most commonly of infectious origin.
Biofilm
A bacterial community that is typically enclosed in an extracellular polymeric substance matrix.
identified. However, mice that were infected with isogenic S. aureus mutants that lacked LukED and HlgAB had the same phenotype as mutants that lacked components of the iron-regulated surface determinant (Isd) haem-iron acquisition system 89 (TABLE 1 ). The differences in activities between cognate and non-cognate leukocidin subunit pairs could be due to differences in cellular receptor binding and in the formation of pores in cell membranes. Studies that investigated the killing of human monocytes by S. aureus in vitro revealed that isogenic strains that lack all of the leukocidins are less efficient at killing human monocytes than any single mutant strain 76 . Moreover, LukAB and PVL have an additive effect in the cytotoxic potential of S. aureus. As such, the leukocidin milieu at the site of infection could influence the contribution of any particular leukocidin in vivo 63, 66 . Leukocidins have also been shown to synergize with other virulence factors to contribute to immune subversion and pathogenesis. For example, the killing of neutrophils by PVL is enhanced by the action of PSMs 8, 90 . Similarly, LukAB has been found to synergize with PVL and PSMs to promote the escape of S. aureus from macrophages after phagocytosis 91 . Very few studies have investigated the synergy between leukocidins and other virulence factors in vivo. Early studies demonstrated that α-toxin, an important PFT for the pathogenesis of S. aureus 13 , and HlgAB and HlgCB together caused septic arthritis more readily than strains that just produced either α-toxin or HlgAB and HlgCB alone 92 . Similar results were observed in a rabbit model of endophthalmitis 93 . More recently, a study that aimed to identify virulence factors that are involved in subverting macrophage functions demonstrated that S. aureus growing as a biofilm can evade phagocytosis owing to the combined activities of LukAB and α-toxin 94 . Importantly, these in vitro observations were confirmed in vivo, as the production of LukAB and α-toxin resulted in enhanced pathogenesis in a mouse model of orthopaedic implant infection 94 . Thus, it is clear that leukocidins are able to synergize with other S. aureus virulence factors to enhance their cytotoxic potential and their contribution to virulence.
Bi-component leukocidins have also been found to antagonize each other 87 . This antagonism is most evident for PVL and LukED. PVL has been shown to block the LukED-mediated lysis of erythrocytes by forming complexes with LukED at the plasma membrane of erythrocytes that impair pore formation 87 (FIG. 2d) . In a series of in vivo bloodstream infections in mice, it was found that S. aureus strains that produced PVL and LukED were less virulent than strains that produced LukED alone 87 . Interestingly, these findings could explain previous studies in which deletion of the pvl locus resulted in increased virulence in several murine 87, [95] [96] [97] and rabbit models of S. aureus infection 98, 99 . The virulence of S. aureus infection is remarkable, given that the organism colonizes many individuals as a commensal 1 . In a murine model of intranasal infection, it was shown that uncoupling the LukED antagonism by PVL promoted colonization of the lungs by S. aureus 87 (FIG. 2d) . Thus, in addition to contributing to acute infection, interactions between leukocidins could contribute to colonization. However, the role of bi-component toxins in colonization remains to be fully understood.
Together, these findings highlight the possibility that bi-component leukocidins exert different activities that result in different phenotypes when they are expressed at the same time, and that to fully understand the contribution of these toxins to the pathophysiology of S. aureus we need to study them as a group.
Therapeutics
Owing to the increase in antibiotic resistance and the lack of new classes of antibiotic that are available to treat bacterial infections, there is a clinical need to develop alternative antimicrobial strategies and an effective S. aureus vaccine. An important consideration in the development of new antibiotics and vaccines that target S. aureus is that bi-component leukocidins kill phagocytes that are required for the clearance of the pathogen 9 . The cellular receptors that are used by leukocidins are candidate drug targets for severe S. aureus infections (FIG. 3) . Blocking interactions between receptors and leukocidins by means of receptor antagonists has protected neutrophils against the action of some leukocidins in vitro 10, 36, 38 ; however, the development of a combination therapy in which several receptor-leukocidin interactions are targeted could lead to adverse reactions resulting from suppressed host immune responses.
Several monoclonal antibodies (mAbs) that neutralize one or more toxins are currently being evaluated in clinical and preclinical trials 22,100,101 and could be used to treat severe infections during the active phase or for the prevention of infections in highrisk groups (FIG. 3) . An engineered bi-specific tetravalent mAb was shown to neutralize PVL and HlgCB in vitro and in an inflammation model in rabbits 102 . More recently, a mAb that neutralizes α-toxin, PVL, HlgAB, HlgCB and LukED was reported to inhibit leukocidin-induced cytotoxicity in vitro and to confer protection against S. aureus infection in mice 103 and rabbits 104 . This broad-neutralizing mAb recognizes a shared conformational epitope in α-toxin and the leukocidin F components. Owing to leukocidin structural dissimilarities, this mAb does not neutralize LukAB 103 . However, the identification of a series of mAbs that specifically neutralize LukAB was recently described 22 ; this included naturally occurring mAbs that were isolated from children who were infected with S. aureus 105 . 
Toxoid
A toxin the toxicity of which has been inactivated chemically or through mutation, whereas its immunogenic properties are maintained.
Opsonophagocytosis
A process of opsonization of a microorganism that results in enhanced phagocytosis of the opsonized microorganism by phagocytes.
compartment, in which it promotes bacterial escape following phagocytosis 37, 63 , is likely to pose challenges for the neutralization of this toxin. Nevertheless, this obstacle could be overcome by combining opsonization and leukocidin neutralization using a fusion antibody platform 101 (FIG. 3) .
Many individuals have large quantities of antibodies that target bi-component leukocidins 70, 106 . Studies that have investigated protection by pre-existing leukocidin-specific antibodies have reported conflicting results 97, [106] [107] [108] [109] , which has made it difficult to evaluate the potential of a vaccine that solely targets leukocidins. The complex pathophysiology of S. aureus, together with the absence of a single dominant virulence factor, necessitates a multivalent approach, and targeting bi-component leukocidins could improve the capacity of phagocytes to clear infection (FIG. 3) . It remains to be determined whether a vaccine that induces broad immunity against all staphylococcal β-barrel PFTs is technically feasible. Recently, a vaccine candidate that was based on a mutant LukS-PV toxoid resulted in a cross-neutralizing immune response against all human leukocidins, except LukAB, in mice 71, 110 . A successful multivalent vaccine will probably need to be complemented with additional targets, such as other immune modulators or cell surface proteins 4, 100, 111 . We hypothesize that previous active and passive immunization strategies against S. aureus have been unsuccessful in clinical trials owing to the exclusive focus on opsonophagocytosis and the reliance on suboptimal animal models of infection 101, 111, 112 . Currently, there are no reliable animal models to study the pathophysiology of S. aureus 48, 111 
Outlook
The identification of host receptors that determine the cellular tropism and species specificity of bi-component leukocidins has advanced our understanding of how these toxins target and kill host cells. Additional advances include uncovering the consequences of receptor binding on host cell function. The notion that leukocidins have multiple cellular effects in a concentration-dependent manner (lytic versus sublytic effects), suggests that the level of toxins produced during infection with S. aureus could have broad effects on the host immune response. Moreover, the discovery that leukocidins can target signalling receptors suggests that these toxins can act as ligands, or even as antagonists, during infection 10, [34] [35] [36] . It is possible that an uncharacterized role of the leukocidins is to block the function of their targeted receptors, thus preventing the migration of leukocytes.
Another important consideration is that the activities and effects of leukocidins could vary in different target cells. A careful examination of how bi-component leuko cidins target and kill different human phagocytes is required, particularly the pathways that are involved in the death of different phagocytes. The expression profiles and the tissue distribution of the known leukocidin receptors support the view that the targets of these toxins are leukocytes. However, the receptors are also expressed in non-myeloid cells, which suggests that leukocidins have the potential to contribute to the pathogenesis of S. aureus in a manner that does not involve targeting leukocytes.
S. aureus is a major pathogen of clinical significance, and leukocidins are a prime example that S. aureus has evolved as a human-specific pathogen. New in vivo models are required that better mimic the human host
. The use of humanized mice has been informative 113, 114 ; however, more work is needed to fully recapitulate the function of human neutrophils in mice. The identification of human specific receptors and recent advances in genome engineering with CRISPR-Cas 115 suggest that developing a mouse model that is compatible with all leukocidins could be possible. Such a model would overcome the current lengthy and variable process of murine humanization, and could enable the study of the role of leukocidins as a group to be assessed in S. aureus infection. These advances are likely to have major implications for the development of effective vaccines and novel therapeutics to prevent and treat infection with S. aureus.
A question that has been challenging to address is why does S. aureus produce so many different toxins that target leukocytes? These toxins are differentially regulated in vitro and in vivo 63, 116 , which supports the hypothesis that S. aureus senses host cues to coordinate the production of leukocidins in a tissue-dependent manner. Moreover, the understanding that leukocidins are able to synergize and antagonize the activities of other leukocidins, stresses the need for further studies that consider that the contribution of leukocidins to infection could change depending on the infection site, the clinical isolate of S. aureus, and the host.
From the perspective of the host, the genes that encode two leukocidin receptors, CCR5 and DARC, are under selective pressure. Cells of individuals that lack these receptors are resistant to leukocidins that target CCR5 and DARC 10, 38 . Moreover, numerous polymorphisms have been found in genes that encode other leukocidin receptors 117 . Future work that investigates the effect of these polymorphisms on host susceptibility to leukocidins could provide insight into observed differences in the susceptibility of humans to infection with S. aureus.
With recent advances in our understanding of how S. aureus bi-component leukocidins target host cells, we are now able to address how these toxins contribute to the pathophysiology of S. aureus, which could lead to the development of novel anti-staphylococcal agents.
